Journal News

A mechanism for remdesivir activity and a platform to test other antivirals

Public–private research partnership between Gilead, Canadian scientists reveals a key residue in the SARS-Cov-2 polymerase
Laurel Oldach
May 7, 2020

Researchers who showed in February that remdesivir blocks coronavirus polymerases are reporting in the Journal of Biological Chemistry that the finding also applies to the novel coronavirus —and they think they can explain the molecular mechanism for how the drug gums up the virus’ gears.

Matthias Götte

In their earlier paper, graduate student Calvin Gordon and professor Matthias Götte of the University of Alberta and co-authors demonstrated that remdesivir can inhibit the viral replicase of the coronavirus that causes Middle East Respiratory Syndrome, or MERS. The study included co-authors from Gilead Sciences, the company that makes the drug.

In the ensuing months, remdesivir, an adenosine-mimicking nucleotide analog developed to treat other viruses, has emerged as the most promising small-molecule treatment for COVID-19. In late April, the National Institute for Allergy and Infectious Diseases reported qualified success of a clinical trial of the drug, and the FDA rapidly issued emergency use authorization for the drug.

Now, using enzymes from the novel coronavirus SARS-nCoV-2 itself instead of the related virus that causes MERS, the research team has shown that remdesivir blocks the SARS-nCoV-2 replicase in a test tube. They also examined a selection of other nucleotide analogs to understand more about whether and how each might work against infection.

The Götte lab studies viral enzymology, and Götte has developed a system for expressing large quantities of viral polymerases from insect cells to enable rapid enzymology studies, informed by a World Health Organization pandemic-preparedness blueprint, which regularly updates a list of the most concerning pathogens. “Coronaviruses like SARS and MERS were always on the list,” Götte said.

Most graduate students don’t finish a paper in their first year in the lab — let alone two papers. Calvin Gordon, a first-year graduate student at the University of Alberta in Edmonton, joined the lab in September 2019. When he began the MERS study in October, the risk of a pandemic was still theoretical. By the time the authors were ready to write up their finding that the MERS polymerase easily incorporates remdesivir but stumbles to a halt a short time later, the first cases of COVID-19 had been reported in Hubei province, China. And by the time they published the discovery, Italy was in lockdown and cases had been reported in both the U.S. and Canada.

Robert Kirchdoerfer, JBC 2020
A cartoon rendition shows how remdesivir stops forward motion by the polymerase from the novel coronavirus..

As soon as the first SARS-CoV-2 genome was published in January, Egor Tchesnokov, a research associate in the lab and co–first author on the new paper, got to work cloning it into their expression system and preparing to test remdesivir’s effect on those enzymes. Their new study, published in April, confirms that, as it did in MERS, the drug works against the enzyme complex the novel coronavirus uses to replicate its genome. This time, thanks to a molecular modeling study run by Gilead’s Jason Perry, the authors are able to explain how it happens.

Using the crystal structure of the polymerase enzyme from another coronavirus — as it happened, researchers from China and Australia published a cryo-EM structure of the novel coronavirus’ replicase on the same day as the second Götte study — and a crystal structure showing how a hepatitis virus enzyme interacts with remdesivir, Perry and other researchers at Gilead put together a computational model of how remdesivir fits into the active site of the novel coronavirus’ replicase.

“As the enzyme incorporates one, two, three more nucleotides, the incorporated remdesivir moves back, so to speak,” Götte said. As it reaches the third position away from the enzyme’s active site, the drug encounters — or causes — a blockage. Because of its unusual 1' modification, it crashes into a specific amino acid, a serine conserved among most coronavirus polymerases, which prevents the enzyme from moving one step forward to incorporate the next RNA base.

“It’s not perfect chain termination; there’s a little read-through,” Götte said. “The specific wish would be to see whether there’s any other nucleotide (analog) out there that would cause a stronger termination.”

Gilead Sciences
Workers in a manufacturing facility at Gilead produce remdesivir.

To find out, the researchers assessed the effect of a variety of other known nucleotide analogs — some of which are in clinical trials — on the viral polymerase. This allowed them both to pinpoint the effect of the drug on a chemical modification at the 1' in its ribose by comparing the features of molecules that did and did not inhibit the polymerase and to make some predictions about other nucleotide analog drug candidates.

For example, they found that, unlike polymerases from other viruses, the enzyme did not recognize drugs with a 2' ribose modification as RNA building blocks. For a drug to inhibit the viral replicase, the replicase must recognize it as a building block of new RNA, and for realistic dosing, it’s best if the enzyme picks up the drug more easily than the drug’s natural counterpart. The researchers found that the SARS-CoV-2 polymerase does not prefer a Gilead drug for hepatitis, sofosbuvir, to its natural counterpart, UTP. In a competition assay, Götte said, “UTP wins, by far. So it is very unlikely based on our data that we would expect potent antiviral activity from sofosbuvir.”

They also investigated the influenza drug favipiravir, which is being tested in fifteen clinical trials around the world for efficacy as a COVID-19 treatment. Like sofosbuvir and remdesivir, favipiravir is a nucleotide analog that has been shown to inhibit other RNA viruses. However, as with sofosbuvir, the SARS-CoV-2 polymerase showed strong selectivity for the natural ribonucleotide over favipiravir, raising some concern about whether favipiravir will have antiviral activity against the new coronavirus. Götte said, “I think it’s very important to reconcile the biochemical data with antiviral data.”

Whether or not remdesivir proves to be an effective treatment for COVID-19, the researchers hope their enzyme platform will help speed up assessment of novel drug candidates as they are developed. They also plan to seek therapeutic combinations of nucleotide inhibitors and drugs with other mechanisms, which could reduce the chances that resistance will develop, Götte said.

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Related articles

Reimagining STEM workforce development as a braided river
Rebecca L. Batchelor, Hendratta Ali, Kathryn G. Gardner-Vandy, Anne U. Gold, Jennifer A. MacKinnon & Pranoti M. Asher

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

St. Jude and maximizing the value of blood
Health Observance

St. Jude and maximizing the value of blood

June 14, 2021

The hospital is most renowned for passing along no costs to families. To facilitate this, the in-house capabilities of St. Jude are second to none. This includes the on-site blood donation facilities.

A balancing game with implications for neurodegenerative disease
Journal News

A balancing game with implications for neurodegenerative disease

June 8, 2021

The relationship between two proteins, one essential to mitochondrial fission and the other found in Alzheimer’s tissue, might hold the key to how disease alters the fission–fusion balance.

Can people vaccinated against COVID-19 still spread the coronavirus?

Can people vaccinated against COVID-19 still spread the coronavirus?

June 6, 2021

Preliminary evidence seems to suggest that someone who’s vaccinated is less likely transmit the virus, but the proof is not yet ironclad.

Addgene expands its collection into antibodies

Addgene expands its collection into antibodies

June 4, 2021

The reagent repository Addgene, known for distribution and quality control of plasmids for open science, is expanding into recombinant antibodies and nanobodies in partnership with NeuroMab.

Study reveals experimental targets for lymphoma research
Journal News

Study reveals experimental targets for lymphoma research

June 3, 2021

An enzyme previously linked to lymphoma development may have more functions than previously thought.

Exploring underappreciated molecules and new cities

Exploring underappreciated molecules and new cities

June 2, 2021

Neurochemist Xianlin Han has been an associate editor for the Journal of Lipid Research since 2019.